Despite the ever-increasing number of patients with dementia worldwide, fundamental therapeutic approaches to this condition have not been established. Epidemiological studies suggest that intake of fermented dairy products prevents cognitive decline in the elderly. However, the active compounds responsible for the effect remain to be elucidated. The present study aims to elucidate the preventive effects of dairy products on Alzheimer’s disease and to identify the responsible component. Here, in a mouse model of Alzheimer’s disease (5xFAD), intake of a dairy product fermented with Penicillium candidum had preventive effects on the disease by reducing the accumulation of amyloid β (Aβ) and hippocampal inflammation (TNF-α and MIP-1α production), and enhancing hippocampal neurotrophic factors (BDNF and GDNF). A search for preventive substances in the fermented dairy product identified oleamide as a novel dual-active component that enhanced microglial Aβ phagocytosis and anti-inflammatory activity towards LPS stimulation in vitro and in vivo. During the fermentation, oleamide was synthesized from oleic acid, which is an abundant component of general dairy products owing to lipase enzymatic amidation. The present study has demonstrated the preventive effect of dairy products on Alzheimer’s disease, which was previously reported only epidemiologically. Moreover, oleamide has been identified as an active component of dairy products that is considered to reduce Aβ accumulation via enhanced microglial phagocytosis, and to suppress microglial inflammation after Aβ deposition. Because fermented dairy products such as camembert cheese are easy to ingest safely as a daily meal, their consumption might represent a preventive strategy for dementia.
Citation: Ano Y, Ozawa M, Kutsukake T, Sugiyama S, Uchida K, Yoshida A, et al. (2015) Preventive Effects of a Fermented Dairy Product against Alzheimer’s Disease and Identification of a Novel Oleamide with Enhanced Microglial Phagocytosis and Anti-Inflammatory Activity. PLoS ONE 10(3): e0118512. doi:10.1371/journal.pone.0118512
Academic Editor: Dong-Gyu Jo, Sungkyunkwan University, Republic of Korea
Received: August 12, 2014; Accepted: January 19, 2015; Published: March 11, 2015
Copyright: © 2015 Ano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: The authors received no specific funding for this work. Kirin Company Ltd. and Koiwai Dairy Products Co., Ltd. provided support in the form of salaries for authors Y.A., T.K., A.Y. and S.S., but did not have any role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.]. Pls also update COI: [We declare the following interests. Yasuhisa Ano, Toshiko Kutsukake and Aruto Yoshida are employed by Kirin Company Ltd., and Shinya Sugiyama is employed by Koiwai Dairy Products Co., Ltd. Koiwai Dairy Foods Co., Ltd. is a subsidiary company of Kirin Company, Ltd., and all research was executed at Kirin Company, Ltd. using Kirin’s sources under a joint research agreement between Kirin and Koiwai. This does not alter our adherence to all of the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Competing interests: The authors declare the following interests: Yasuhisa Ano, Toshiko Kutsukake and Aruto Yoshida are employed by Kirin Company Ltd., and Shinya Sugiyama is employed by Koiwai Dairy Products Co., Ltd. Koiwai Dairy Foods Co., Ltd. is a subsidiary company of Kirin Company, Ltd., and all research was executed at Kirin Company, Ltd. using Kirin’s sources under a joint research agreement between Kirin and Koiwai. This does not alter the authors’ adherence to all of the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
With aged populations growing rapidly around the world, cognitive decline and dementia are becoming an increasing burden not only on patients and their families, but also on national healthcare systems. Alzheimer’s disease is a progressive irreversible brain disorder, symptoms of which include memory loss, confusion, impaired judgment and loss of language skills, and the number of affected individuals is rising sharply. Because cognitive function declines in accordance with an accumulation of Amyloid β (Aβ) in the brain, Aβ deposition is a crucial part of the pathology .
Recent pathological and immunological studies revealed that chronic inflammation following Aβ deposition in the brain is closely associated with Alzheimer’s disease pathology [2–4]. Microglia play unique immunological roles including the removal of apoptotic cells and waste such as Aβ through phagocytosis, as well as host defense against virus infection in the central nervous system [5–6]. In the Alzheimer’s brain, however, microglia infiltrate the region around the Aβ plaques, become excessively activated, and produce large amounts of inflammatory cytokines and chemokines, such as tumor necrosis factor-α (TNF-α), macrophage inflammatory protein-1α (MIP-1α), reactive oxygen (ROS) and nitric oxide (NO) [7–9]. These products, which are chronically generated by microglia, after Aβ deposition are toxic to neurons and cause neuronal cell death [7, 10–11].
Numerous reports suggest that controlling microglial activities is effective in the prevention and cure of Alzheimer’s disease and cognitive decline [12–14]. Epidemiological studies suggest that prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), including the common medication ibuprofen, significantly reduce the risk for Alzheimer’s disease [15–16]. Consistent with epidemiological research, chronic ibuprofen treatment was found to significantly suppress microglial inflammation and the development of Aβ pathology in a transgenic model mouse of Alzheimer’s disease . However, side effects in the gastrointestinal tract, liver and kidney caused by inhibiting cyclooxygenase I preclude the widespread use of NSAIDs in preventing the disease. Therefore, alternative treatments to Alzheimer’s disease and cognitive decline need to be explored and, as a result, preventive approaches based on diet, exercise and learning are attracting increasing attention.
Several recent epidemiological studies suggest that consumption of fermented dairy products may reduce the risk of cognitive decline in the elderly and prevent dementia including Alzheimer’s disease [18–20]. However, the underlying mechanism and the active compounds remain to be elucidated.
In the present study, the preventive effects of fermented dairy products were evaluated using a transgenic mouse model of Alzheimer’s disease, with a particular focus on microglial activities. In addition, after animal evaluation, compounds in dairy products were screened to identify components capable of enhancing microglial Aβ phagocytosis and anti-inflammatory activity.
Materials and Methods
Pregnant C57BL/6J mice, 8-week-old C57BL/6J male mice, and 6-week-old CD-1 male mice were purchased from Charles River Japan (Tokyo, Japan). Alzheimer’s disease model mice, B6SJL-Tg mice (APPSwFlLon,PSEN1*M146L*L286V, http://jaxmice.jax.org/strain/006554.html, ) were purchased from Jackson Laboratory (CA, USA). Mice under 3 months of age were fed with a standard purified rodent growth diet (AIN-93G, Oriental Yeast, Tokyo, Japan), and those over 3 months with a maintenance diet (AIN-93M, Oriental Yeast).
B6SJL-Tg mice were maintained in the experimental facility at the University of Tokyo, and the experiments were approved by the Animal Care and Use Committee of the University of Tokyo and conducted in strict accordance with their guidelines. Pregnant C57BL/6J mice, 8-week-old C57BL/6J mice, and 6-week-old CD-1 mice were maintained in Kirin Company Ltd, and the experiments were approved by the Animal Experiment Committee of Kirin Company Ltd and conducted in strict accordance with their guidelines. All efforts were made to minimize suffering.
Preparation of Penicillium candidum-fermented dairy product sample
Penicillium (P.) candidum-fermented dairy products (camembert cheese) were prepared according to a general manufacture procedure. In brief, sterilized milk was fermented with Lactococcus lactis to reduce the pH, and treated with calf rennet. The aggregated curds were fermented by P. candidum. The fermented products were then freeze-dried and delipidated with n-hexane (Wako, Tokyo, Japan) to remove triglyceride. The nutrient composition of the extracted samples was calculated by Japan Food Research Laboratories (Tokyo, Japan).
AIN-93G and AIN-93M diets (Oriental Yeast) containing 2% (w/w) fermented sample were prepared by a conventional procedure, and each diet with or without sample was adjusted to contain the same calories according to the nutrient composition of the extracted sample.
Analysis of Aβ1–42 deposition and chronic inflammation in transgenic murine brain
To evaluate the effects of fermented dairy products on Alzheimer’s disease, 3-month-old transgenic and wild-type female mice were fed a diet with or without fermented sample (2% w/w) for three months (n = 11 mice in each group). At the age of 6 months, the mice were euthanized and the brains were removed. The left hemisphere of the brain was homogenated in RIPA buffer (Wako) with a multi-beads shocker (Yasui Kikai, Osaka, Japan). After centrifugation at 500,000 × g for 20 min, the total protein concentration of the supernatant was measured with a BCA protein assay kit (ThermoScientific, Yokohama, Japan). To quantify Aβ1–42 (Wako), MIP-1α (R&D systems, MN, USA), TNF-α (eBiosciences, CA, USA), IL-1β (eBiosciences), synaptophysin (Life Science Inc., FL, USA), BDNF (Promega, WI, USA), GDNF (Promega), and NGF (Promega) in the hippocampus, an appropriate ELISA kit was used. The right hemispheres were fixed in 10% formalin (Wako) and analyzed immunohistochemically using the following specific antibodies: anti-Aβ1–42 (polyclonal, Invitrogen, CA, USA), anti-Iba-1 (polyclonal, Wako), and anti-MIP-α (polyclonal, R&D systems).
Preparation of lipid extract
The surface and inside of dairy product fermented with or without P. candidum were crushed in a mortar after lyophilization, and extracted with n-hexane, chloroform and then with methanol. For gas chromatography mass spectrometer (GC/MS) analysis, the lyophilized samples were suspended in methanol containing 1N KOH, and saponified at 80°C for 2 hours. The lipid fraction was obtained as previously described  with some modifications. Vehicle (chloroform: water = 10:9) was added to the fraction (final ratio: approximately 1:1:0.9, v/v/v; chloroform:methanol:water), which was then vortexed for 20 min and centrifuged at 3000rpm for 10 min. The lower phase was dried under a stream of N2 at 40°C, dissolved in acetone, and filtered through a Polytetrafluoroethylene membrane disc (Millipore, MA, USA).
The analysis for primary fatty acid amides using GC/MS has been previously described . An Agilent Technologies Network GC/MS system (7890 GC with 5975 mass detector) was used for the analysis with an HP-5MS capillary column (0.25 mm internal diameter, 0.25 μm film thickness, 30 m long, Agilent Technologies). The temperature was initially held at 80°C for 1 min, raised up to 280°C at a rate of 30°C per min, and then held at 280°C for 23 min. The total run time was 30.7 min. Helium was used as a carrier gas with a flow of 1.2 ml/min. Ionization was obtained by electron impact (electron energy, 70 eV). The temperature of the injection port and the transfer line was 250°C. Splitless injection was used with a volume of 1 μl.
Primary microglia cell culture
Brain cells were obtained from newborn C57BL/6J mice or 6-month-old B6SJL-Tg mice by papaine treatment using a Neural Tissue Dissociation Kit (P) (Miltenyi Biotec, MA, USA). The cells were treated with 2 μg/ml of anti-CD11b antibody conjugated to microbeads (Miltenyi Biotec), and CD11b-positive cells were isolated by magnetic cell sorting (MACS). Isolated cells with more than 90% purity were plated in a poly-D-lysine (PDL)-coated 96-well plate (BD Biosciences, MA, USA) and cultured in DMEM/F-12 (Gibco, CA, USA) medium supplemented with 10% fetal calf serum (Gibco) and 100 U/ml of penicillium/streptomycin (Sigma-Aldrich, MO, USA).
In vitro cytokine production assay
Microglia isolated from newborn C57BL/6J mice and 6-month-old B6SJL-Tg mice were plated at a density of 30,000 per well in a PDL-coated plate, treated with each extracted sample and with fatty acids mainly contained in milk (linoleic acid, linolenic acid, oleic acid, stearic acid, conjugated linoleic acid, Sigma-Aldrich) and oleamide (Sigma-Aldrich) for 12 hours, and then treated with by lipopolysaccharide (LPS, 5 ng/ml, Sigma-Aldrich) and interferon-γ (IFN-γ, 0.5 ng/ml, R&D systems) for 12 hours. After LPS stimulation, supernatants were applied to a TNF-α production assay and cells were evaluated for the expression of cell markers using a FACS Canto II flow cytometer (BD Bioscience) after staining with the following antibodies: 2 μg/ml of anti-CD11b-APC-Cy7 (BD Pharmingen), 1 μg/ml of anti-CD206-PerCP-Cy5.5 (BioLegend, CA, USA), 1 μg/ml of anti-CD68-APC (BioLegend), and 2 μg/ml of anti-CD80-PE (eBiosciences).
To measure intracellular cytokine production, microglial cells were treated with a leukocyte activation cocktail using BD GolgiPlug (BD Biosciences) for 12 hours and with a BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences), and then stained with following antibodies: anti-MIP-1α-PE, 2 μg/ml (eBiosciences); anti-TNF-α-FITC, 1 μg/ml (eBiosciences); anti-interleukin-1β (IL-1β)-FITC, 2 μg/ml (eBiosciences); anti-IL-12p40/p70-APC, 2 μg/ml (BD Pharmingen); anti-CD11b-APC-Cy7, 2 μg/ml; and anti-CD206-PerCP-Cy5.5, 1 μg/ml. The cells were analyzed by flow cytometry.
In vivo anti-inflammatory assay
Six-week-old CD-1 male mice were orally given 50 mg/kg of oleamide dissolved in vehicle including 5% ethanol, 5% cremophor and 90% saline, once a day for 3 days. We confirmed that 10 ml/kg oral administration of vehicle did not induce inflammation in the brain (data not shown; n = 7 mice in each group). Thirty minutes after the last administration, the mice were deeply anesthetized with sodium pentobarbital (Kyoritsu Seiyaku, Tokyo, Japan) and injected intracerebroventricularly with 0.25 mg/kg of LPS (L7895, Sigma). LPS or distilled water (for sham-operated controls) was injected by hand into the cerebral ventricle in a volume of 3 μL as described previously [24–27]. Briefly, a micro-syringe with a 27-gauge stainless steel needle, 2 mm in length, was used for micro injection. The needle was inserted unilaterally 1 mm to the right of the midline point equidistant from each eye, at an equal distance between the eyes and the ears and perpendicular to the plane of the skull (anteroposterior, − 0.22 mm from the bregma; lateral, 1 mm from the bregma). LPS was delivered gradually within 30 s. The needle was taken out after waiting 30 s. All mice exhibited normal behavior after they recovered from the anesthetic. Three hours later, the mice were euthanized, the cerebral cortex and hippocampus in one hemisphere were homogenated in RIPA buffer, and the concentration of TNF-α (eBioscience) and MIP-1α (R&D systems) in the supernatants was quantified by ELISA. The hippocampus in the other hemisphere was dissociated with papaine, stained for microglia with the above-mentioned antibodies, and analyzed by flow cytometry as previously described.
Phagocytosis of 6-carboxyfluorescein-labeled Aβ1–42 by microglia
Microglial phagocytosis of 6-carboxyfluorescein-labeled Aβ1–42 (Aβ-FAM, AnaSpec, CA, USA) was evaluated by a plate-based assay. Microglial cells isolated from newborn mice were plated at a density of 50,000 cells per well in a PDL-coated 96-well plate and incubated with 500 nM Aβ-FAM for 24 hours after either oleic acid (Sigma-Aldrich) or oleamide (Sigma-Aldrich) pretreatment for 12 hours. After the medium was removed, extracellular Aβ-FAM was quenched with 0.2% trypan blue, pH 4.4. Cellular fluorescence was measured at 485 nm excitation/535 nm emission using a plate reader (Molecular Device, CA, USA).
In vivo phagocytosis assay
Eight-week-old C57BL/6J male mice were orally given 0, 10 or 50mg/kg of oleamide dissolved in vehicle including 5% ethanol (Wako), 5% cremophor (Sigma-Aldrich) and 90% saline (Otsuka) once a day for 3 days (n = 5 mice in wach group). Three hours after the last administration, microglia in the brain were isolated by MACS, and the phagocytotic activity of the microglia was measured using Aβ-FAM as described above. Populations of CD206- and CD11b-positive cells and the expression of cell markers were analyzed using a flow cytometer after staining with 2 μg/ml of anti-CD36-APC antibody (BioLegend), and 2 μg/ml of anti-CD11b-APC-Cy7 antibody (BD Pharmingen).
All values were expressed as the mean ± SEM. Data from the production assays for cytokines, chemokines, neurotrophic factors and synaptophysin, and from in vitro antagonist assays were analyzed by two-way ANOVA, followed by the Tukey-Kramer test. Data from the in vitro assays were analyzed by one-way ANOVA, followed by Dunnett’s test or Student’s t test. All statistical analyses were performed using the Ekuseru-Toukei 2012 software program (Social Survey Research Information, Tokyo, Japan).
Intake of the fermented dairy product substantially reduces Aβ burden and inflammation
The amount of soluble Aβ1–42 in the brain of 5xFAD transgenic mice was significantly decreased by 17% in the group fed with the dairy sample (Fig. 1A). The insoluble Aβ1–42 in cerebral cortex detected immunohistochemistry was decreased by 21% in the sample group but the reduction was not significant (Fig. 1B, C, D). Pathological staining examination by immunohistochemistry revealed that the Aβ1–42 burden was reduced by 21% in the cerebral cortex but 12.5% in the hippocampus. Iba-1-positive microglia had massively infiltrated and engulfed Aβ1–42 (Fig. 1E), and produced MIP-1α (Fig. 1F). The enhanced production of MIP-1α in the transgenic mice was significantly suppressed by administration of the dairy product (Fig. 1H).
Three-month-old 5xFAD transgenic mice were fed a control diet (CTL) or a diet containing 2% (w/v) extract (sample) for 3 months. A, Quantification of soluble Aβ1–42 in the brain by ELISA. B and C, Immunohistochemical detection of Aβ1–42 distribution in the cerebral cortex. D, Immunohistochemical analysis of Aβ1–42 distribution in the cerebral cortex. E and F, Immunofluorescent detection of Iba-1-positive microglia (red), and either Aβ1–42 or MIP-1α (green), respectively. G and H, Quantification of cytokines (TNF-α) and chemokine (MIP-1α) in the hippocampus by ELISA. Error bars represent the means ± SEM of 11 mice per group. **p < 0.01 and *p < 0.05. Scale bars represent 200 μm (B and C) and 20 μm (E and F)
Intake of the fermented dairy product increases hippocampal neurotrophic factors and synaptophysin
The production of BDNF and GDNF in the hippocampus was significantly lower in the transgenic mice than in wild-type mice. In contrast, the production of these factors was significantly higher in the mice fed with dairy product than in the control mice (Fig. 2A, B, respectively). The expression of synaptophysin, a neuronal synapse marker was correlated with the productions of neurotrophic factors. (Fig. 2D). There were no significant differences in the amount of NGF (Fig. 2C) and synaptophysin.
A, B and C, Measurement of BDNF, GDNF and NGF, respectively, in the hippocampus. D, Measurement of synaptophysin in the hippocampus. Error bars represent means ± SEM of 11 mice per group. *p < 0.05.
Anti-inflammatory activity of extracts from the surface of the dairy product
The surface and inside part of the dairy product fermented with or without P. candidum were separately treated with methanol after triglyceride removal by n-hexane and chloroform. The weight of the methanol extract, which mainly contains fatty acids, was increased only on the surface of fermented dairy products (data not shown). The extract from the surface of the fermented dairy product suppressed the production of TNF-α by microglia in a concentration-dependent manner, whereas the extracts from the inside of the product and those without fermentation did not (Fig. 3A).
A, Isolated microglia were stimulated with 5 ng/ml of LPS and 0.5 ng/ml of IFN-γ after pretreatment with each methanol extract, and TNF-α production in the supernatant was quantified by ELISA. Error bars represent means ± SEM (n = the number of cheese samples) B, Chromatogram of the extract from the surface of the P. candidum-fermented product and oleamide as a standard. C and D, Mass spectra of Peak 7 and an oleamide standard, respectively. E and F, Chemical structural formula of oleamide and oleic acid, respectively.
P. candidum fermentation generates oleamide
Gas chromatography-mass spectrometry showed a peak identical to oleamide in the extract from the surface of the dairy product fermented with P. candidum (Fig. 3B). The mass spectrum of this peak (Fig. 3C) corresponded to the reference standard of oleamide (Fig. 3D). Oleamide (Fig. 3E) is fatty acid oleic acid (Fig. 3F), and was not detected in dairy products that had not been fermented with P. camdidum.
Oleamide has microglial anti-inflammatory activity in vitro
Oleamide suppressed microglial TNF-α production in a concentration-dependent fashion, and enhanced microglial anti-inflammatory activity more strongly than oleic acid (Fig. 4A). The ratios of MIP-1α-positive microglia to CD11b-positive microglia and TNF-α-positive microglia to CD11b-positive microglia were significantly lower after oleamide treatment (Fig. 4B, C, respectively). Microglia treated with oleamide also showed a lower expression of the inflammatory cell markers CD68 and CD80 in CD11b-positive microglia (Fig. 4D, E, respectively). In addition, oleamide significantly suppressed TNF-α production in microglia derived from the Aβ-deposited brain of Alzheimer’s disease model mice (Fig. 4F).
A, Isolated microglia from C57BL/6J newborn were stimulated with 5 ng/ml of LPS and 0.5 ng/ml of IFN-γ after pretreatment with oleic acid or oleamide, and then TNF-α in the supernatant was measured by ELISA. B and C, Isolated microglia were pretreated with oleamide and incubated with PMA, ionomycin, and BD Golgiplug for 12 hours. The ratio (%) of or TNF-α-positive cells or MIP-1α-positive cells to CD11b-positive cells (B and C, respectively). D and E, Expression of CD68 and CD80 in CD11b-positive cells (D and E, respectively). F, Isolated microglia from the brain of 6-month-old 5xFAD transgenic mice were stimulated with 5 ng/ml LPS and 0.5 ng/ml IFN-γ after pretreatment with oleamide, and TNF-α in the supernatant was measured by ELISA. Error bars represent the means ± SEM of 3 wells per group. *p < 0.05 and **p < 0.01.
Oleamide enhances microglial anti-inflammatory activity in vivo
Intracerebroventricular injection of LPS significantly increased the production of TNF-α and MIP-1α, but there was no significant difference between the sham and vehicle-treated groups and the group given 50 mg/kg of oleamide and LPS in either the hippocampus (Fig. 5A, C, respectively) or the cerebral cortex (Fig. 5B, D, respectively). Flow cytometric analysis revealed that the production of TNF-α and MIP-1α in CD11b-positive microglia was significantly lower in the group administered oleamide (Fig. 5E, F, respectively). In addition, the expression of I-A/I-E and CD68 was significantly reduced (Fig. 5G, H, respectively) and that of PDL-2 was significantly increased (Fig. 5I) in the group of mice given oleamide.
CD-1 mice (n = 7/group) were orally given 50 mg/kg of oleamide once a day for 3 days and then injected intracerebroventricularly with either saline or 0.25 mg/kg of LPS. A and B, Quantification of TNF-α in the cerebral cortex and hippocampus, respectively. C and D, Quantification of MIP-1α in the cerebral cortex and hippocampus, respectively. E and F, The ratio (%) of TNF-α-positive or MIP-1α-positive cells to CD11b-positive cells. G, H, and I, Expression of I-A/I-E, CD68, and PDL-2, respectively, in CD11b single-positive cells. Error bars represent the means ± SEM of 7 mice per group. *p < 0.05 and **p < 0.01.
Oleamide enhances microglial phagocytosis in vitro and in vivo
Oleamide at concentrations of 100–1000 nM was found to enhance microglial phagocytosis of Aβ1–42 in a concentration-dependent manner in vitro, whereas oleic acid did not show activity at all (Fig. 6A). In addition, oral administration of 50 mg/kg of oleamide significantly enhanced the brain microglial phagocytosis of Aβ (Fig. 6B) and significantly enhanced the expression of CD36 in CD11b-positive microglia in the hippocampus (Fig. 6C).
A, Aβ phagocytotic activity was measured in vitro using isolated microglia pretreated with either oleic acid or oleamide. The value is the ratio of fluorescence to the vehicle. Error bars represent the means ± SEM (n = the number of wells when we examined phagocytosis of Aβ1–42) B and C, Effect of treatment with oleamide in vivo on microglial phagocytotic activity. After the oral administration of 0, 10, or 50 mg/kg of oleamide once a day for 3 days and isolation of microglia from the brain, phagocytotic activity and the expression of CD36 were measured. B, Cellular Aβ-FAM was measured after isolated microglia were treated with 500 nM Aβ-FAM for 5 hours and quenched extracellular Aβ-FAM. C, Expression of CD36 in CD11b single-positive cells. Error bars represent the means ± SEM of 5 mice per group. *p < 0.05 and **p < 0.01.
In the present study, the preventive effects of ingesting a fermented dairy product on Alzheimer’s disease, which have previously been reported only epidemiologically, were investigated in a mouse model of Alzheimer’s disease. In mice fed with the fermented dairy product, the deposition of Aβ in the brain was significantly reduced. Microglia play a crucial role in maintaining the brain environment by removing waste products such as amyloid, aged synapses and apoptotic cells via phagocytosis [28–31]. The results of the present study suggest that ingredients in the fermented dairy product contribute to the activation of microglial phagocytosis, resulting in a reduction of Aβ in the brain.
In Alzheimer’s disease, chronic inflammation in the brain exacerbates the pathological condition and cognitive decline because inflammation is toxic to neurons and suppresses the production of neurotrophic factors such as BDNF, GDNF and NGF [32–35]. In the present study, the inflammation induced by Aβ deposition in the transgenic mice was suppressed when the mice were fed with the fermented dairy product. In addition, the production of chemokine (MIP-1α) was remarkably increased in the hippocampus of the transgenic mice and significantly reduced by ingestion of the fermented dairy product. It has been reported that MIP-1α and TNF-α produced by microglia exacerbate the Alzheimer’s pathology [36–37]. The production of both BDNF and GDNF in the hippocampus was also significantly reduced in the model mouse, whereas their production in mice fed with the fermented dairy product was significantly recovered to the levels observed in wild-type mice. It has been suggested that suppression of inflammation contributes to the production of neurotrophic factors, the survival of neuronal synapses and the retention of cognitive function. In the brain, immunological phenomena are mainly regulated by microglia; as a result, it seems likely that some components of the fermented dairy product may regulate the microglial inflammatory response, leading to a suppression of the pathology.
In the transgenic mouse model of Alzheimer’s disease, intake of the fermented dairy product showed preventive effects on development of the disease. Phagocytosis of Aβ by microglia may be essential for clearance of Aβ in Alzheimer’s disease; however, excessively activated microglia also produce several neurotoxic products, such as ROS, NO, cytokines and chemokines, leading to neuronal death [7–9]. Therefore, our results suggest that some ingredients in the fermented dairy product may enhance microglial anti-inflammatory activity and phagocytosis.
Our findings revealed that a certain dairy substance generated during fermentation with P. candidum is crucial for microglial regulation because the fatty acid extract had high anti-inflammatory effects. In general, linoleic acid and linolenic acid in dairy products are known to have an anti-inflammatory effect. In the present study, linoleic acid and linolenic acid were also identified, but oleamide as a novel ingredient with anti-inflammatory properties was identified from the dairy product fermented with P. candidum. As compared with linoleic acid and linolenic acid, oleamide has much higher anti-inflammatory activity. In addition, oleamide was identified as a potent dual-active component capable of enhancing both phagocytosis and anti-inflammatory activity. Oleamide is also known as an endogenous substance that binds to cannabinoid (CB) receptors as an agonist [38–39]. However, no previous studies have reported that dairy products contain oleamide. Oleamide is the amide of oleic acid, and is synthesized from oleic acid and ammonia by enzymatic amidation . Oleic acid is abundant in dairy products, and ammonia is generated during the fermentation and maturation of cheese. It is also reported that oleamide is converted from oleic acid via the amidation activity of lipase in a bacteria . These reports suggest that oleamide is generated in the dairy product from oleic acid during fermentation with P. candidum. In support of this, in the present study oleamide was detected mainly on the surface part of camembert cheese, where P. candidum grows well, but was not detected in the dairy product without P. candidum fermentation.
As mentioned above, oleamide has high anti-inflammatory activity. A previous study using an LPS-stimulated murine microglial cell line (BV-2) showed that oleamide suppressed the production of NO and PGE2 . Another study revealed that oleamide suppressed microglial NO production via CB2 receptors, which are mainly expressed on the surface of immune cells (monocytes, macrophages, and B cells). In the present study, oleamide suppressed the productions of MIP-1α and TNF-α, which were predominantly produced in the brain of the Alzheimer’s model mice. Oleamide was also found to have an in vivo anti-inflammatory effect in the brain of the Alzheimer’s model mouse. In addition, orally administered oleamide was found to have a potent anti-inflammatory activity on microglia in the LPS-stimulated brain by suppressing the inflammatory cell markers I-A/I-E and CD68, up-regulating the anti-inflammatory cell marker PDL-2, and reducing the inflammatory factors MIP-1α and TNF-α. Therefore, the regulation of microglial activity with oleamide might contribute to the effective prevention of Alzheimer’s disease.
On the other hand, oleamide activates PPAR-γ receptors in cells , and its agonist enhances the phagocytotic activity of monocytes . PPAR-γ has recently been receiving increasing attention as a target for Alzheimer’s disease therapy [45–47], so activation of PPAR-γ might be involved in the enhancement of microglial phagocytosis by oleamide. Further studies will elucidate the mechanism of oleamide activate microglial phagocytosis. Oleic acid has no effects on microglia phagocytosis; therefore, amidation of oleic acid must be crucial for this activity. In addition, orally administered oleamide enhanced microglial phagocytosis in the brain and increased the expression of CD36, which is important for uptake of Aβ .
In summary, it has been revealed that oleamide in fermented dairy product enhances microglial phagocytosis and suppresses inflammation. Oleamide might prevent Alzheimer’s disease by regulating microglia to a phenotype preferable for maintaining the brain environment. Although camembert alone might not prevent dementia, a well-balanced diet that combines camembert with agreeable foods like red wine or fish is expected to reduce the risk of dementia. Red wine and fish have been proven to contain resveratrol and omega-3 fatty acids respectively, which are beneficial for preventing Alzheimer’s disease. Recent reports suggesting that a Mediterranean diet is associated with lower risk of dementia are supportive of a food culture that combines dairy products with wines and fish dishes [48–49]. Fermented dairy products such as camembert cheese are easy and safe to consume frequently, and might helpful for dementia prevention.
Conceived and designed the experiments: YA KU AY HN. Performed the experiments: YA MO TK. Analyzed the data: YA MO TK. Contributed reagents/materials/analysis tools: SS. Wrote the paper: YA HN.
- 1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–356. pmid:12130773 doi: 10.1126/science.1072994
- 2. Miklossy J. Chronic inflammation and amyloidgenesis in Alzheimer’s disease—role of Spirochetes. J Alzheimers Dis. 2008; 13: 381–391. pmid:18487847
- 3. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154–169. doi: 10.1111/j.1365-2567.2009.03225.x. pmid:20561356
- 4. Fung A, Vizcaychipi M, Lyoyd D, Wan Y, Ma D. Central nervous system inflammation in disease related conditions: mechanistic prospects. Brain Res. 2012; 1446: 144–155. doi: 10.1016/j.brainres.2012.01.061. pmid:22342162
- 5. Tremblay MÈ, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn M. The role of microglia in the healthy brain. J Neurosci. 2011; 31: 16064–16069. doi: 10.1523/JNEUROSCI.4158-11.2011. pmid:22072657
- 6. Blank T, Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2013; 61: 62–70. doi: 10.1002/glia.22372. pmid:22740320
- 7. McGeer EG, MCGeer PL. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 2010; 19: 355–361. doi: 10.3233/JAD-2010-1219. pmid:20061650
- 8. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010; 6: 193–201. doi: 10.1038/nrneurol.2010.17. pmid:20234358
- 9. Rezai-Zadeh K, Gate D, Gowing G, Town T. How to get from here to there: macrophage recruitment in Alzheimer’s disease. Curr Alzheimr Res. 2011; 8: 156–163. pmid:21345166 doi: 10.2174/156720511795256017
- 10. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlak SL, et al. Amyloid-β deposition is Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 1998; 70: 2212–2215. pmid:9572310 doi: 10.1046/j.1471-4159.1998.70052212.x
- 11. Sugama S, Takenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H. Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets 2009; 8: 277–284. pmid:19754411 doi: 10.2174/187152809789352249
- 12. Malm T, Koistinaho M, Muona A, Magga J, Koistinaho J. The role and therapeutic potential of monocytic cells in Alzheimer’s disease. Glia 2010; 58: 889–900. doi: 10.1002/glia.20973. pmid:20155817
- 13. Naert G, Rivest S. The role of microglia cell subsets in Alzheimer’s disease. Curr Alzheimer Res. 2011; 8: 151–155. pmid:21418002 doi: 10.2174/156720511795256035
- 14. Fernández PL, Britton GB, Rao KS. Potential immunotargets for Alzheimer’s disease treatment strategies. J Alzheimers Dis. 2013; 33: 297–312. doi: 10.3233/JAD-2012-121222. pmid:23001712
- 15. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and Histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523–530. pmid:8544901 doi: 10.1016/0197-4580(95)00049-k
- 16. Stewart WF, Kawas C, Corrada M, Meter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurobiology 1997; 48: 626–632. doi: 10.1212/wnl.48.3.626
- 17. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. 2000; 20: 5709–5714. pmid:10908610
- 18. Crichton GE, Murphy KJ, Bryan J. Dairy intake and cognitive health in middle-aged South Australians. Asia Pac J Clin Nutr. 2010; 19: 161–171. pmid:20460228
- 19. Camfield DA, Owen L, Scholey AB, Pipingas A, Stough C. Dietary constituents and neurocognitive health in ageing. Br J Nutr. 2011; 106: 159–174. doi: 10.1017/S0007114511000158. pmid:21338538
- 20. Ozawa M, Ninomiya T, Ohara T, Doi Y, Uchida K, Hata J, et al. Dietary patterns and risk of dementia in an elderly Japanese population: the Hisayama Study. Am J Clin Nutr. 2013; 97: 1076–1082. doi: 10.3945/ajcn.112.045575. pmid:23553168
- 21. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26: 10129–10140. pmid:17021169 doi: 10.1523/jneurosci.1202-06.2006
- 22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37: 911–917. pmid:13671378
- 23. Sultana T, Johnson ME. Sample preparation and gas chromatography of primary fatty acid amides. J Chromatogr A 2006; 1101: 278–285. pmid:16266715 doi: 10.1016/j.chroma.2005.10.027
- 24. Bessis A, Béchade C, Bernard D, Roumier A. Microglia control of neuronal death and synaptic properties. Glia 2007; 55: 233–238. pmid:17106878 doi: 10.1002/glia.20459
- 25. Fiala M, Cribbs DH, Rosenthal M, Bernard G. Phagocytosis of amyloid-beta and inflammation: two face of innate immunity in Alzheimer’s disease. J Alzheimers Dis. 2007; 11: 457–463. pmid:17656824
- 26. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010; 117: 949–960. doi: 10.1007/s00702-010-0433-4. pmid:20552234
- 27. Tremblay MÈ. The role of microglia and synapses in the healthy CNS: novel insights from recent studies. 2011; Neuron Glia Biol. 7: 67–76. doi: 10.1017/S1740925X12000038. pmid:22418067
- 28. Cotman CW. The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. 2005; Neurochem Res. 30: 877–881. pmid:16187222 doi: 10.1007/s11064-005-6960-y
- 29. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des. 2010; 16: 2766–2778. pmid:20698820 doi: 10.2174/138161210793176572
- 30. Sastre M, Richardson JC, Gentleman SM, Brooks DJ. Inflammatory risk factors and pathologies associated with Alzheimer’s disease. 2011; Curr Alzheimer Res. 8: 132–141. pmid:21345169 doi: 10.2174/156720511795256062
- 31. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science 2013; 339: 156–161. doi: 10.1126/science.1227901. pmid:23307732
- 32. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am J Pathol. 1998; 153: 31–37. pmid:9665462 doi: 10.1016/s0002-9440(10)65542-3
- 33. Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer’s disease. J Alzheimers Dis. 2005; 8: 369–375. pmid:16556968
- 34. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83–87. pmid:8900284 doi: 10.1038/384083a0
- 35. Boger DL, Henriksen SJ, Cravatt BF. Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des. 1998; 4: 303–314. pmid:10197045
- 36. Slotema WF, Sandoval G, Guieysse D, Straathof AJ, Marty A. Economically pertinent continuous amide formation by direct lipase-catalyzed amidation with ammonia. Biotechnol Bioeng 2003; 82: 664–669. pmid:12673765 doi: 10.1002/bit.10613
- 37. Awasthi NP, Singh RP. Lipase-catalyzed synthesis of fatty acid amide (erucamide) using fatty acid and urea. J Oleo Sci. 2007; 56: 507–509. pmid:17898456 doi: 10.5650/jos.56.507
- 38. Oh YT, Lee JY, Lee J, Lee JH, Kim JE, Ha J, et al. Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-kappaB activation in BV2 murine microglial cells. 2010; Neurosci Lett. 474: 148–153. doi: 10.1016/j.neulet.2010.03.026. pmid:20298753
- 39. Dionisi M, Alexander SP, Bennett AJ. Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro. Lipids Health Dis. 2012; 11: 51. doi: 10.1186/1476-511X-11-51. pmid:22584002
- 40. Moore KJ, Rose ED, Fitzgerald ML, Randow F, Andresson LP, Altshuler D, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nature Med. 2001; 7: 41–47. pmid:11135614
- 41. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanism underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficts in a murine model of Alzheimer’s disease. J Neurosci. 2012; 32: 10117–10128. doi: 10.1523/JNEUROSCI.5268-11.2012. pmid:22836247
- 42. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARγ/RXRα-induced and CD36-mediated microglia amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenillin 1 mice. J Neurosci. 2012; 32: 17321–17331. doi: 10.1523/JNEUROSCI.1569-12.2012. pmid:23197723
- 43. Lourenco MV, Ledo JH. Targeting Alzheimer’s pathology through PPARγ signaling: modulation of microglial function. J Neurosci. 2012; 33:5083–5084. doi: 10.1523/jneurosci.0172-13.2013
- 44. Lourida I, Soni M, Thomson-Coon J, Purandare N, Lang IA, Ukoumunne OC, et al. Mediterranean Diet, cognitive function, and dementia: a systematic review. Epidemiology 2013; 24: 479–489. doi: 10.1097/EDE.0b013e3182944410. pmid:23680940
- 45. Vassallo N, Screrri C. Mediterranean diet and dementia of the Alzheimer type. Curr Aging Sci. 2013; 6: 150–162. pmid:23030130 doi: 10.2174/1874609811306020003
- 46. Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996; 706: 181–193. pmid:8822355 doi: 10.1016/0006-8993(95)01032-7
- 47. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Aβ25–35. Behav Brain Res. 2007; 180: 139–145. pmid:17420060 doi: 10.1016/j.bbr.2007.03.001
- 48. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, et al. Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol. 2009; 157: 1270–1277. doi: 10.1111/j.1476-5381.2009.00295.x. pmid:19552690
- 49. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res. 2010; 1352: 176–186. doi: 10.1016/j.brainres.2010.07.006. pmid:20627092